US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

32.59 +0.94 (+2.97%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
4 Analysts Have This to Say About Celldex Therapeutics ↗
 
Via Benzinga
News headline image
Celldex Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Why Celldex Therapeutics Shares Are Trading Higher Today ↗
 
Via Benzinga
News headline image
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data ↗
 
Via Benzinga
News headline image
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market ↗
Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET 
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today? ↗
The Federal Reserve's interest rate hike announcements have the potential to cause significant volatility in the stock market. 
Via Benzinga
News headline image
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Topics Death
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing... 
Via TheNewswire.com
Topics Death
News headline image
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients ↗
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX< 
Via Benzinga
News headline image
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Participate in Upcoming November Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Earnings Perspective: Return On Capital Employed ↗
Celldex Therapeutics (NASDAQ:CLDX) brought in sales totaling $163 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 56.2%, resulting in a loss of $36.00... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >